TapewireFind a company

person · Reporting owner

WIINBERG ULF

Disclosed activity across 2 companies

Tapewire entity
71
SEC CIK
0001187314

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
AGENUS INCAGEN · Entity 5774DirectorOctober 01, 2024October 03, 2024
MiNK Therapeutics, Inc.INKT · Entity 52DirectorSeptember 01, 2026September 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AGENUS INC

Report date October 01, 2024 · Filed October 03, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Deferred Stock UnitsSEC Table II · derivative / convertible securityDirect19,500.664 Reported balance After 2024-10-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-10-01 · Grant · Acquired 3,423.478 · Balance 19,500.664

F1: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3: $7.49 per Deferred Stock Unit acquired on October 1, 2024. The price of each Deferred Stock Unit acquired on October 1,2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Filing footnotes · ownership attribution and instrument terms

F1: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F2: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F3: $7.49 per Deferred Stock Unit acquired on October 1, 2024. The price of each Deferred Stock Unit acquired on October 1,2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

MiNK Therapeutics, Inc.

Report date September 01, 2026 · Filed September 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect23,929 Reported balance After 2026-09-01 transaction · row 1
1 source row

Row 1 · 2026-09-01 · Grant · Acquired 1,279 · Balance 23,929

F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Common StockSEC Table I · non-derivativeIndirectSee footnote27,830 Reported balance Holding disclosure · report date 2026-09-01 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 27,830

F2: Shares are held in an irrevocable trust for the benefit of Mr. Wiinberg's family.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

F2: Shares are held in an irrevocable trust for the benefit of Mr. Wiinberg's family.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 01, 2026 Filed Sep 2, 2026 15:10 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 1,279 $10.95 $14,005.05
Disclosure

SEC source: 0001193125-26-379575 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,929

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
June 01, 2026 Filed Jun 2, 2026 20:05 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 1,131 $12.38 $14,001.78
Disclosure

SEC source: 0001193125-26-253461 · ownership.xml · nonDerivative · entry 2

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,650

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
March 02, 2026 Filed Jun 2, 2026 20:05 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 1,285 $10.90 $14,006.50
Disclosure

SEC source: 0001193125-26-253461 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,519

F3 · price: Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.

Read SEC document
January 02, 2026 Filed Jan 6, 2026 22:24 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantStock Option (Right to Buy) · Derivative 5,395 $0.00 Strike: $11.12 $0.00
Disclosure

SEC source: 0001193125-26-004786 · ownership.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,395

Underlying: Common Stock · 5,395 shares

Expires 2036-01-02

F1 · derivative.exercise_date: Option vests on February 2, 2026, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

Read SEC document
December 01, 2025 Filed Dec 3, 2025 21:10 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 1,263 $11.09 $14,006.67
Disclosure

SEC source: 0001193125-25-306675 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,234

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
September 09, 2025 Filed Sep 11, 2025 20:05 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantStock Option (Right to Buy) · Derivative 3,225 $0.00 Strike: $15.36 $0.00
Disclosure

SEC source: 0001193125-25-201314 · ownership.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,225

Underlying: Common Stock · 3,225 shares

Expires 2035-09-09

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

Read SEC document
September 02, 2025 Filed Sep 3, 2025 21:33 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 1,011 $13.86 $14,012.46
Disclosure

SEC source: 0001193125-25-195095 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,971

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 20:05 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 1,953 $7.17 $14,003.01
Disclosure

SEC source: 0000950170-25-081611 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,960

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:05 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 1,593 $8.79 $14,002.47
Disclosure

SEC source: 0000950170-25-033525 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,007

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
December 01, 2024 Filed Dec 3, 2024 15:35 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 20,476 $0.73 $14,947.48
Disclosure

SEC source: 0000950170-24-132518 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,181

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
October 01, 2024 Filed Oct 3, 2024 12:40 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 3,423.478 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-112007 · ownership.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500.664

Underlying: Common Stock · 3,423.478 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $7.49 per Deferred Stock Unit acquired on October 1, 2024. The price of each Deferred Stock Unit acquired on October 1,2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 12:22 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 18,295 $0.82 $15,001.90
Disclosure

SEC source: 0000950170-24-103745 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,705

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:05 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 2,121.119 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-079585 · ownership.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,077.186

Underlying: Common Stock · 2,121.119 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $12.08 per Deferred Stock Unit acquired on July 1, 2024. The price of each Deferred Stock Unit acquired on July 1,2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
June 03, 2024 Filed Jun 5, 2024 18:24 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 15,077 $0.99 $14,926.23
Disclosure

SEC source: 0000950170-24-069212 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,410

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
April 01, 2024 Filed Apr 1, 2024 20:20 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 38,635.459 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-039351 · ownership.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 279,121.341

Underlying: Common Stock · 38,635.459 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $0.66 per Deferred Stock Unit acquired on April 1, 2024. The price of each Deferred Stock Unit acquired on April 1, 2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 23:00 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 15,790 $0.95 $15,000.50
Disclosure

SEC source: 0000950170-24-026426 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,333

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
February 05, 2024 Filed Apr 22, 2024 20:05 UTC AGENUS INC AGEN · Entity 5774 GrantStock Option · Derivative 5,000 $0.00 Strike: $12.60 $0.00
Disclosure

SEC source: 0000950170-24-046417 · ownership.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2034-02-05

F1 · derivative.exercise_date: The Stock Options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan on February 5, 2024 and will vest on February 5, 2025. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 100,000 Stock Options with an exercise price of $0.63.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 11:05 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 30,956.376 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-001478 · ownership.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,485.882

Underlying: Common Stock · 30,956.376 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $0.83 per Deferred Stock Unit acquired on January 2, 2024. The price of each Deferred Stock Unit acquired on January 2, 2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
December 01, 2023 Filed Dec 5, 2023 23:05 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 14,424 $1.04 $15,000.96
Disclosure

SEC source: 0000950170-23-068312 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,543

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
November 15, 2023 Filed Nov 17, 2023 21:22 UTC AGENUS INC AGEN · Entity 5774 PurchaseCommon Stock 25,000 $0.76 $19,000.00
Disclosure

SEC source: 0000950170-23-064833 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,063

F1 · shares: Represents open market purchase of common stock for cash.

Read SEC document
October 02, 2023 Filed Oct 4, 2023 21:01 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 18,001.063 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-23-051963 · ownership.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,529.506

Underlying: Common Stock · 18,001.063 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $1.42 per Deferred Stock Unit acquired on October 2, 2023. The price of each Deferred Stock Unit acquired on October 2, 2023 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediatlely preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. This amount also includes a downward adjustment of 75.02 Deferred Stock Units in respect of the grant dated July 3, 2023, as the average closing price used for such calculation incorrectly reflected a stock split and was increased on October 2, 2023 to $1.61 per Deferred Stock Unit.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 21:00 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 9,590 $1.46 $14,001.40
Disclosure

SEC source: 0000950170-23-046773 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,119

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

F2 · balance_after: In Table 1 of the Form 4 filed on June 2, 2023, the amount of securities acquired and price (column 4) and amount of securities beneficially owned following reported transaction (column 5) were erroneously reported. On June 1, 2023, 7,778 RSUs were acquired at a price of $1.80 each, resulting in a total amount of securities beneficially owned following the reported transaction of 50,529 instead of 50,706 as erroneously reported.

Read SEC document
July 03, 2023 Filed Jul 6, 2023 20:30 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 16,018.322 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-23-017124 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,528.442

Underlying: Common Stock · 16,018.322 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $1.60 per Deferred Stock Unit acquired on July 3, 2023. The price of each Deferred Stock Unit acquired on July 3, 2023 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediat1ely preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
June 14, 2023 Filed Jun 17, 2023 00:03 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantStock Option (Right to Buy) · Derivative 22,500 $0.00 Strike: $2.27 $0.00
Disclosure

SEC source: 0000899243-23-015837 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

Read SEC document
June 01, 2023 Filed Jun 2, 2023 23:40 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 7,955 $1.76 $14,000.80
Disclosure

SEC source: 0000899243-23-014410 · doc4.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,706

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
April 03, 2023 Filed Apr 3, 2023 19:58 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 11,901.641 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-23-010207 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,510.12

Underlying: Common Stock · 11,901.641 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $2.153 per Deferred Stock Unit acquired on April 3, 2023. The price of each Deferred Stock Unit acquired on April 3, 2023 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediat1ely preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 20:23 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 6,699 $2.09 $14,000.91
Disclosure

SEC source: 0000899243-23-006928 · doc4.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,751

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
January 08, 2023 Filed Jan 10, 2023 00:02 UTC AGENUS INC AGEN · Entity 5774 GrantStock Option · Derivative 100,000 $0.00 Strike: $2.40 $0.00
Disclosure

SEC source: 0000899243-23-001356 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2033-01-08

F1 · derivative.exercise_date: Options of Common Stock were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan (the "2019 Plan") on January 8, 2023. Options will vest on January 8, 2024.

Read SEC document
January 03, 2023 Filed Jan 4, 2023 16:25 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 9,893.822 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-23-000503 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,608.479

Underlying: Common Stock · 9,893.822 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $2.590 per Deferred Stock Unit acquired on January 3, 2023. The price of each Deferred Stock Unit acquired on January 3, 2023 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
December 01, 2022 Filed Dec 5, 2022 23:27 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 5,364 $2.61 $14,000.04
Disclosure

SEC source: 0000899243-22-037698 · doc4.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,052

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

F2 · balance_after: Includes shares inadvertently excluded from a Form 4 filed on September 19, 2022.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 17:09 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 9,862.289 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-032920 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,714.657

Underlying: Common Stock · 9,862.289 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $2.598 per Deferred Stock Unit acquired on October 3, 2022. The price of each Deferred Stock Unit acquired on October 3, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
September 15, 2022 Filed Sep 19, 2022 23:06 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantCommon Stock 10,688 $2.62 $28,002.56
Disclosure

SEC source: 0000899243-22-031528 · doc4.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,688

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Read SEC document
July 19, 2022 Filed Jul 21, 2022 19:21 UTC MiNK Therapeutics, Inc. INKT · Entity 52 PurchaseCommon Stock 16,661 $1.39 $23,208.77
Disclosure

SEC source: 0000899243-22-026460 · doc4.xml · nonDerivative · entry 2

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 298,300

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $1.37 - $1.51. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Read SEC document
July 18, 2022 Filed Jul 21, 2022 19:21 UTC MiNK Therapeutics, Inc. INKT · Entity 52 PurchaseCommon Stock 3,339 $1.33 $4,437.53
Disclosure

SEC source: 0000899243-22-026460 · doc4.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 281,639

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $1.31 - $1.44. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Read SEC document
July 01, 2022 Filed Jul 6, 2022 19:50 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 13,854.975 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-025320 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 143,852.368

Underlying: Common Stock · 13,854.975 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $1.850 per Deferred Stock Unit acquired on July 1, 2022. The price of each Deferred Stock Unit acquired prior to July 1, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
April 01, 2022 Filed Apr 5, 2022 22:26 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 9,307.809 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-013870 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,997.393

Underlying: Common Stock · 9,307.809 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $2.753 per Deferred Stock Unit acquired on April 1, 2022. The price of each Deferred Stock Unit acquired prior to April 1, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
March 09, 2022 Filed Mar 11, 2022 21:08 UTC MiNK Therapeutics, Inc. INKT · Entity 52 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $2.89 $0.00
Disclosure

SEC source: 0000899243-22-010698 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-03-09

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

Read SEC document
February 04, 2022 Filed Feb 8, 2022 23:10 UTC AGENUS INC AGEN · Entity 5774 GrantStock Option (Right to Buy) · Derivative 100,000 $0.00 Strike: $2.39 $0.00
Disclosure

SEC source: 0000899243-22-005239 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-02-04

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan, as amended, and will vest on February 4, 2023.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 20:24 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 6,391.991 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-000866 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,689.584

Underlying: Common Stock · 6,391.991 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $4.009 per Deferred Stock Unit acquired on January 3, 2022. The price of each Deferred Stock Unit acquired prior to January 3, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
October 01, 2021 Filed Oct 5, 2021 23:13 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 4,451.32 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-039305 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,297.593

Underlying: Common Stock · 4,451.32 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $5.757 per Deferred Stock Unit acquired on October 1, 2021. The price of each Deferred Stock Unit acquired prior to October 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
July 01, 2021 Filed Jul 2, 2021 22:00 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 6,707.279 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-027312 · doc4.xml · derivative · entry 2

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,846.273

Underlying: Common Stock · 6,707.279 shares

Expires not disclosed

F2 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F4 · price: $3.820 per Deferred Stock Unit acquired on July 1, 2021. The price of each Deferred Stock Unit acquired prior to July 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F3 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F3 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
June 16, 2021 Filed Jun 21, 2021 20:17 UTC AGENUS INC AGEN · Entity 5774 Exercise / conversionCommon Stock 16,853 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-024971 · doc4.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,063

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On June 16, 2020, Mr. Wiinberg was granted 16,853 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 16, 2021, this award vested in full and Mr. Wiinberg was issued the underlying 16,853 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

F1 · price: On June 16, 2020, Mr. Wiinberg was granted 16,853 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 16, 2021, this award vested in full and Mr. Wiinberg was issued the underlying 16,853 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

Read SEC document
June 15, 2021 Filed Jul 2, 2021 22:00 UTC AGENUS INC AGEN · Entity 5774 GrantStock Option · Derivative 100,000 $0.00 Strike: $3.18 $0.00
Disclosure

SEC source: 0000899243-21-027312 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests in full on December 17, 2022.

Read SEC document
April 01, 2021 Filed Apr 5, 2021 22:22 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 6,959.905 Not disclosed Not disclosed
Disclosure

SEC source: 0001745285-21-000015 · primary_doc.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,098.9

Underlying: Common Stock · 6,959.905 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.682 per Deferred Stock Unit acquired on April 1, 2021. The price of each Deferred Stock Unit acquired prior to April 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 22:27 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 5,896.535 Not disclosed Not disclosed
Disclosure

SEC source: 0001745285-21-000004 · primary_doc.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,179.09

Underlying: Common Stock · 5,896.535 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.780 per Deferred Stock Unit acquired on January 4, 2021. The price of each Deferred Stock Unit acquire prior to January 4, 2021 is the average of the closing price for the Company's Common Stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's Common Stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's Common Stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
December 17, 2020 Filed Dec 21, 2020 19:44 UTC AGENUS INC AGEN · Entity 5774 GrantStock Option (Right to buy) · Derivative 100,000 $0.00 Strike: $3.70 $0.00
Disclosure

SEC source: 0001745285-20-000051 · primary_doc.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The Stock Option vests in full on December 17, 2021 (provided Mr. Wiinberg continues to serve on the board on such date).

Read SEC document
October 01, 2020 Filed Oct 1, 2020 19:00 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 6,464.583 Not disclosed Not disclosed
Disclosure

SEC source: 0001745285-20-000035 · primary_doc.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,282.555

Underlying: Common Stock · 6,464.583 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.964 per Deferred Stock Unit acquired on October 1, 2020. The price of each Deferred Stock Unit acquired prior to October 1, 2020 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquire pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to be a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to be a director of the Company.

Read SEC document
July 01, 2020 Filed Jul 1, 2020 22:50 UTC AGENUS INC AGEN · Entity 5774 GrantDeferred Stock Units · Derivative 8,398.143 Not disclosed Not disclosed
Disclosure

SEC source: 0001745285-20-000024 · primary_doc.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,817.972

Underlying: Common Stock · 8,398.143 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.051 per Deferred Stock Unit acquired on July 1, 2020. The price of each Deferred Stock Unit acquired prior to July 1, 2020 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Read SEC document
June 19, 2020 Filed Jun 23, 2020 20:33 UTC AGENUS INC AGEN · Entity 5774 Exercise / conversionRestricted Stock Unit · Derivative 20,338 Not disclosed Not disclosed
Disclosure

SEC source: 0001745285-20-000020 · primary_doc.xml · derivative · entry 2

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,338 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

F1 · shares: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

F1 · price: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

F1 · derivative.exercise_date: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

F1 · derivative.expiration_date: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

Read SEC document
June 19, 2020 Filed Jun 23, 2020 20:33 UTC AGENUS INC AGEN · Entity 5774 Exercise / conversionCommon Stock 20,338 Not disclosed Not disclosed
Disclosure

SEC source: 0001745285-20-000020 · primary_doc.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,210

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

F1 · price: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.